Brief: Panbela Therapeutics Announces Third Independent Safety Review Of Phase 3 Aspire Clinical Trial DSMB Recommended Continuation With No Trial Modification
24/06/2024 15:18
June 24 (Reuters) - Panbela Therapeutics Inc PBLA.PK :
* PANBELA THERAPEUTICS ANNOUNCES THIRD INDEPENDENT SAFETY
REVIEW
OF PHASE 3 ASPIRE CLINICAL TRIAL DSMB RECOMMENDED CONTINUATION
WITH NO TRIAL MODIFICATION
* PANBELA THERAPEUTICS INC: INTERIM SURVIVAL ANALYSIS STILL
EXPECTED EARLY 2025
* PANBELA THERAPEUTICS INC: ENROLLMENT POSITIONS CO FOR
ENROLLMENT
COMPLETION BY Q1 2025
Source text for Eikon: ID:nGNX5CSFPk
Further company coverage: PBLA.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Panbela Therapeutics
See all newsBrief: Panbela Therapeutics Announces Third Independent Safety Review Of Phase 3 Aspire Clinical Trial DSMB Recommended Continuation With No Trial Modification
Brief: Nasdaq Notifies Panbela Therapeutics Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard
Brief: Panbela Announces Pricing of Approximately $9 Mln Public Offering
U.S. STOCKS ON THE MOVE-Fisker, Best Buy, NuStar Energy
Brief: Panbela Therapeutics Announces Exercise Of Warrants And Issuance Of New Warrants